ABI
ACAD icon

Adamant Biomedical Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Adamant Biomedical Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$6.51M Buy
205,000
+170,000
+486% +$4.82M 1.56% 19
2014
Q3 		$867K Buy
+35,000
New +$819K 0.22% 80

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adamant Biomedical Investments's ACAD Position: Q4 2014 in Review

Adamant Biomedical Investments increased its Acadia Pharmaceuticals (ACAD) stake by 486% in Q4 2014, buying an estimated $4.82M and bringing the position to 205,000 shares worth $6.51M. The position accounts for 1.56% of the portfolio, ranked #19.

Adamant Biomedical Investments first reported a position in ACAD in Q3 2014 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold ACAD as of Q4 2014.

  • Adamant Biomedical Investments held 205,000 shares of Acadia Pharmaceuticals worth $6.51M as of Q4 2014.
  • Adamant Biomedical Investments bought 170,000 Acadia Pharmaceuticals shares in Q4 2014, an estimated $4.82M.
  • Acadia Pharmaceuticals made up 1.56% of Adamant Biomedical Investments's portfolio in Q4 2014, its #19 holding.
  • Adamant Biomedical Investments first reported a position in Acadia Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 182 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.